Da Rocha, Mathieu Neto
Guiot, Melanie
Nicod, Clementine
Trad, Rim
Bouquet, Lucie
Haderbache, Rafik
Warda, Walid
Baurand, Pierre-Emmanuel
Jouanneau, Chloe
Dulieu, Philippe
Deschamps, Marina
Ferrand, Christophe http://orcid.org/0000-0003-0119-3919
Funding for this research was provided by:
Association Nausicaa Combat sa Leucémie (Gift 2017-03, 2018, 2019, 2020, 2021)
Cancéropôle Grand Est (2020)
Association Semons l’espoir (nonprofit association - loi 1901 FR (2020-2021)
Ligue contre la Cancer, Comité du Doubs Montbeliard (2020-2021)
The MiMedi project (DOS0060162/00, the European Union through the European Regional Development Fund of the Region Bourgogne-Franche-Comte [grant no. FC0013440])
French Blood Center (2018, 2019)
EU project T2EVOLVE (grant no. 945393)
UMR1098 RIGHT is a member of the OPALE Carnot Institute
Grand Besancon Metropole (2019-2022)
Article History
Received: 4 January 2022
Accepted: 23 November 2022
First Online: 2 December 2022
Declarations
:
: Not applicable.
: Not applicable.
: <b>CF:</b> consulting: Gilead. Research grant: Daiichi Sankyo<b>CF and MD : founders and shareholders of CanCell Therapeutics WW, CN</b> and <b>MNdR:</b> employees of CanCell Therapeutics<b>P-EB</b>, <b>CJ</b>, and <b>PD:</b> employees of Diaclone SAS